Phase 1 Non-Alcoholic Fatty Liver Disease Trial, Recruiting (NCT07553663)

Phase 1 Non-Alcoholic Fatty Liver Disease Trial, Recruiting NCT07553663 Sponsor: Corcept Therapeutics Condition: Non-Alcoholic Fatty Liver Disease

Printed from Voxsanity (voxsanity.com.au) — NCT07553663 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Non Alcoholic Fatty Liver Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Your liver has been assessed using a special scan (FibroScan) showing signs of liver stiffness and fat, OR you have had a liver biopsy within the last 12 months showing a certain level of liver inflammation, fat, and scarring.
Your liver enzyme levels (a blood test called AST) are above a certain level — above 17 U/L for women or above 20 U/L for men (this does not apply if you had an eligible recent liver biopsy).
You have been diagnosed with type 2 diabetes, OR you have at least 2 of the following: high fasting blood sugar, high blood pressure, high triglycerides (a type of fat in the blood), low "good" (HDL) cholesterol, or being overweight/having a large waist measurement.

Who may not be able to join:

Women who are pregnant, trying to become pregnant, or currently breastfeeding.
People whose BMI is below 18 or above 45 (a measure of body weight relative to height).
People who regularly drink more than a moderate amount of alcohol (more than 20g per day for women or 30g per day for men) in the past year, or who score highly on an alcohol use questionnaire.
People who have already had a liver transplant or are expected to need one during the study.
People who have type 1 diabetes.
People who have type 2 diabetes that is not well controlled (based on a blood test called HbA1c being 9.5% or above).
People who have any other ongoing liver disease.
People who have cirrhosis (severe liver scarring), or evidence of it from scans, blood tests, or biopsy.
People whose liver has stopped working properly (hepatic decompensation) (confirm with trial site).
There may be additional criteria not listed here that could affect eligibility.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 23 July 2026

Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Aprille Espinueva, PharmD, Corcept Therapeutics

Phone: 210-253-3426

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07553663

Sponsor: Corcept Therapeutics

Phase: Phase 1

Status: Recruiting

Condition: Non-Alcoholic Fatty Liver Disease

Trial contact: 210-253-3426

More information: https://clinicaltrials.gov/study/NCT07553663

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Your liver has been assessed using a special scan (FibroScan) showing signs of liver stiffness and fat, OR you have had a liver biopsy within the last 12 months showing a certain level of liver inflammation, fat, and scarring.
Your liver enzyme levels (a blood test called AST) are above a certain level — above 17 U/L for women or above 20 U/L for men (this does not apply if you had an eligible recent liver biopsy).
You have been diagnosed with type 2 diabetes, OR you have at least 2 of the following: high fasting blood sugar, high blood pressure, high triglycerides (a type of fat in the blood), low "good" (HDL) cholesterol, or being overweight/having a large waist measurement.

Who may not be able to join:

Women who are pregnant, trying to become pregnant, or currently breastfeeding.
People whose BMI is below 18 or above 45 (a measure of body weight relative to height).
People who regularly drink more than a moderate amount of alcohol (more than 20g per day for women or 30g per day for men) in the past year, or who score highly on an alcohol use questionnaire.
People who have already had a liver transplant or are expected to need one during the study.
People who have type 1 diabetes.
People who have type 2 diabetes that is not well controlled (based on a blood test called HbA1c being 9.5% or above).
People who have any other ongoing liver disease.
People who have cirrhosis (severe liver scarring), or evidence of it from scans, blood tests, or biopsy.
People whose liver has stopped working properly (hepatic decompensation) (confirm with trial site).
There may be additional criteria not listed here that could affect eligibility.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 23 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 1

Sponsor

Corcept Therapeutics

Registry

ClinicalTrials.gov

Start date

30 April 2026

Est. completion

30 October 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Assessment of miricorilant PK parameters; Assessment of miricorilant PK parameters; Assessment of miricorilant PK parameters; Assessment of miricorilant PK parameters; Assessment of miricorilant PK parameters; Assessment of miricorilant PK parameters; Assessment of miricorilant PK parameters; Assessment of miricorilant PK parameters

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov